Molecular basis of the spectrum of skeletal complications of neoplasia

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 2903-2908

  Goltzman, David ^a,b   Karaplis, Andrew C ^c   Kremer, Richard ^a,b   Rabbani, Shafaat A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Hypercalcemia of malignancy; Osteogenesis; Osteolysis; Parathyroid hormone related peptide; Phosphate regulating endopeptidase in x linked hypophosphatemic rickets; Phosphaturia; Urokinase

Indexed keywords

CALCIUM; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHATE; PROTEINASE; UROKINASE;

BONE DEVELOPMENT; BONE METASTASIS; CONFERENCE PAPER; HYPERCALCEMIA; MOLECULAR DYNAMICS; OSTEOBLAST; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; PATHOGENESIS; PHOSPHATURIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0034659929     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<2903::aid-cncr4>3.0.co;2-g     Document Type: Conference Paper

References (30)

1. Gutman AB, Tyson TL, Gutman EB. Serum calcium, inorganic phosphorus and phosphatase activity in hyperparathyroidism, Paget's disease, multiple myeloma and neoplastic disease of the bones. Arch Intern Med 1936;57:379-413.
2. Albright F. Case records of the Massachusetts General Hospital (case 27461). N Engl J Med 1941;225:789-91.
3. Lafferty FW. Pseudohyperparathyroidism. Medicine 1966;45: 247-60.
4. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE, et al. Biochemical evaluation of patients with cancer-associated hypercalcemia. Evidence for humoral and non-humoral groups. N Engl J Med 1980;303:1377-83.
5. Rabbani SA, Mitchell J, Roy DR, Kremer R, Bennett HPJ, Goltzman D. Purification of peptides with parathyroid hormone-like bioactivity from human and rat malignancies associated with hypercalcemia. Endocrinology 1986;118: 1200-10.
6. Moseley JM, Kubota M, Diefenbach-Jagger D, Wettenhall REH, Kemp BE, Suva J, et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 1987;84:5048-52.
7. Stewart AF, Wu T, Goumas D, Burtis WJ, Broadus AE. N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of parathyroid hormone-like and parathyroid hormone-unlike domains. Biochem Biophys Res Commun 1987;146:672-8.
8. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung C, et al. Parathyroid hormone-like protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest 1987;80:1803-07.
9. Yasuda T, Banville D, Hendy GN, Goltzman D. Characterization of the human parathyroid hormone-like peptide gene: functional and evolutionary aspects. J Biol Chem 1989; 264:7720-25.
10. Rabbani SA, Mitchell J, Roy DR, Hendy GNH, Goltzman D. Influence of the amino-terminus on in vitro and in vivo biological activity of synthetic parathyroid hormone-like peptide of malignancy. Endocrinology 1988;123:2709-16.
11. Henderson J, Shustik C, Kremer R, Rabbani SA, Hendy GN, Goltzman D. Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. J Bone Miner Res 1989;5:105-13.
12. Henderson J, Bernier S, D'Amour P, Goltzman D. Effects of passive immunization against parathyroid hormone (PTH)-like peptide and PTH in hypercalcemic tumor-bearing rats and normocalcemic controls. Endocrinology 1990;127: 1310-8.
13. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cell in vivo. Int J Cancer 1999;80:257-64.
14. Truong UN, Papavasiliou V, Goltzman D, Kremer R. Parathyroid hormone related peptide (PTHRP) is a prognostic indicator in hypercalcemic cancer patients with skeletal or extra skeletal metastasis. Bone Miner Res 1999;14:S189.
15. Haq M, Kremer R, Goltzman D, Rabbani SA. A vitamin D analogue (EB1089) inhibits parathyroid hormone related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest 1993;91:2416-22.
16. El Abdaimi K, Papavasiliou V, Rabbani SA, Rhim JS, Goltzman D, Kremer R. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer. Cancer Res 1999;59:3325-8.
17. Aklilu F, Park M, Goltzman D, Rabbani SA. Induction of parathryoid hormone-related peptide by the ras oncogene: role of ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy. Cancer Res 1997; 57:4517-22.
18. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
19. Kong YY, Yoshida H, Sarosi I, Tan HL, Timm E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
20. El Abdaimi K, Papavasiliou V, Binderup D, Goltzman D, Kremer R. The vitamin D analog EB1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Bone Miner Res 1998;23(5):S186,1158.
21. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997;80:S1581-7.
22. Achbarou A, Kaiser S, Tremblay G, Ste-Marie L-G, Brodt P, Goltzman D, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994;54:2372-7.
23. Rabbani SA, Desjardins J, Bell AW, Banville D, Goltzman D. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990;173:1058-64.
24. Appella E, Robinson EA, Ulrich SJ, Stopelli MP, Corti A, Cassani G, et al. The receptor binding sequence of urokinase: a biological function for the growth factor module of proteases. J Biol Chem 1987;262:4437-40.
25. Rabbani SA, Rajwans N, Achbarou A, Murthy KK, Goltzman D. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. FEBS Lett 1994;338: 69-74.
26. Rabbani SA, Gladu I, Mazar AP, Henkin J, Goltzman D. Induction in human osteoblastic cells (SaOS2) of the early response genes for jun and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 1997;172:137-45.
27. Ryan EA, Reiss E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med 1984;77:501-12.
28. Scriver CR, Tenenhouse HS. X-linked hypophosphataemia: an appreciation of a classic paper and a survey of progress since 1958. J Inherited Metabol Dis 1992;15:610-24.
29. Anonymous. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995;11: 130-6.
30. Lipman ML, Panda D, Bennett HPJ, Henderson JE, Shane E, Shen Y, et al. Cloning of human PEX cDNA; Expression, subcellular localization, and endopeptidase activity. J Biol Chem 1998;273(22):13729-37.